WilliamPFayMD
Cardiology • Columbia, MOAdult Congenital Heart Disease, Interventional Cardiology
Professor, Internal Medicine, University of Missouri, Columbia School of Medicine
Dr. Fay is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Hospital Dr
Columbia, MO 65212Phone+1 573-882-2296Fax+1 573-884-7743
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Cardiovascular Disease, 1986 - 1990- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1985 - 1986
University of MichiganResidency, Internal Medicine, 1982 - 1985
University of Illinois College of MedicineClass of 1982
Certifications & Licensure
MO State Medical License 2004 - 2025
MI State Medical License 1990 - 2015
MN State Medical License 1985 - 1990
IA State Medical License 1986 - 1989- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 110 citationsPlatelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanismsWilliam P. Fay, Daniel T. Eitzman, Amy D. Shapiro, Edwin L. Madison, David Ginsburg
Blood. 1994-01-15 - 186 citationsBrief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.William P. Fay, Amy D. Shapiro, Judy L. Shih, Raymond R. Schleef, David Ginsburg
The New England Journal of Medicine. 1992-12-10 - 112 citationsThrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine lifeMariko Nagashima, Zheng-Feng Yin, Lei Zhao, Kathy White, Yanhong Zhu
The Journal of Clinical Investigation. 2002-01-01
Other
- Thrombotic and hemorrhagic disorders due to abnormal fibrinolysisFay WP
http://www.uptodate.com/contents/thrombotic-and-hemorrhagic-disorders-due-to-abnormal-fibrinolysis
UpToDate, Wolters Kluwer Health - 2013-03-20
Press Mentions
NextGen Will Raise University's Research PowerJanuary 1st, 2020
Through MU Health Partnership, Moberly Regional Medical Center to Offer Cardiac CareAugust 3rd, 2016
Grant Support
- Roles Of Plasminogen Activator Inhibitor-1 And Vitronectin In Failure Of CoronaryNational Heart, Lung, And Blood Institute2010–2011
- Regulation Of Fibrinolysis At Sites Of Arterial InjuryNational Heart, Lung, And Blood Institute1997–2007
- Regulation Of Platelet-Dependent ThrombosisNational Heart, Lung, And Blood Institute2004
- Regulation Of Platelet-Dependent ThrombosisNational Heart, Lung, And Blood Institute2000–2003
- Structure/Function In Plasminogen Activator Inhibitor-1National Heart, Lung, And Blood Institute1992–1996
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
